Acute Generalized Exanthematous Pustulosis Induced by Piroxicam: a Case Report

Total Page:16

File Type:pdf, Size:1020Kb

Acute Generalized Exanthematous Pustulosis Induced by Piroxicam: a Case Report Drug Watch Acute generalized exanthematous pustulosis induced by piroxicam: A case report Y. Cherif, Moez Jallouli, M. Mseddi1, H. Turki1, Z. Bahloul ABSTRACT Departments of Internal Medicine, and 1Dermatology, Hedi Chaker Acute generalized exanthematous pustulosis (AGEP) is a severe adverse cutaneous reaction University Hospital, Sfax, Tunisia characterized by an acute episode of sterile pustules over erythematous‑edematous skin. The main triggering drugs are antibiotics, mainly beta‑lactam and macrolides. Received: 27‑06‑2013 Non‑steroid anti‑inflammatory drugs may rarely be responsible. We describe a case of Revised: 30‑07‑2013 a woman with AGEP, who presented with generalized pustulosis lesions after the use Accepted: 21‑01‑2014 of piroxicam for renal colic. The diagnosis was confirmed by the clinical and histological correlations and the dermatosis resolved after withdrawal of the drug. Correspondence to: Dr. Moez Jallouli, KEY WORDS: Acute generalized exanthematous pustulosis, adverse drug reactions, E‑mail: [email protected] piroxicam, pustulosis Introduction glimepiride and dyslipidemia treated with simvastatin. She was given oral piroxicam 20 mg/day by her primary care physician for Cutaneous adverse drug reactions are estimated to be treatment of renal colic. There were no other medications prior about 30% of all adverse drug reactions and observed in to starting piroxicam. At 4 days after starting oral piroxicam, 2‑3% of hospitalized patients.[1] The cutaneous drug reaction she developed a generalized itchy eruption consisting of multiple shows various clinical features and mechanisms.[1,2] Acute papules that sometimes coalesced to larger and scaly plaques, generalized exanthematous pustulosis (AGEP) is a generalized pustular eruption that is primarily drug‑induced in probably on a background of widespread erythema with associated more than 90% of case.[3] In a few cases infections including multiple 2‑3 mm pustules [Figure 1]. The mucus membranes, cytomegalovirus[4] and parvovirus B19,[5] chlamydia and palms and soles were spared. Nikolsky’s sign was negative. The mycoplasma pneumoniae[6,7] have been suspected. A spider remaining physical examination was normal. Her white blood cell 3 3 3 3 bite was recently implicated as a possible cause of AGEP in count was 10.8 × 10 /mm , with a 6.42 × 10 /mm neutrophil three patients.[8] Although various drugs have been implicated count. The remaining laboratory tests performed were within in this condition, there are no reported cases of AGEP caused the normal range: creatinine 61.1 µmol/l, erythrocyte rate by oral oxicams in the current literature. We report here a case sedimentation at 30 mm/h, C‑reactive protein 19.48 mg/l and of AGEP induced by piroxicam. Figure 1: Multiple papules and pustules that coalesced to larger and Case Report scaly plaques This was a case report of a 61‑year‑old female patient who was admitted to internal medicine department for renal colic. She had no history of psoriasis or any other skin disorder. The patient had a history of longstanding arterial hypertension for 3 years treated with captopril, indapamide, nifedipine and diabetes mellitus for 3 years treated with glibenclamide, Access this article online Quick Response Code: Website: www.ijp‑online.com DOI: 10.4103/0253‑7613.129332 232 Indian Journal of Pharmacology | April 2014 | Vol 46 | Issue 2 Cherif, et al.: Piroxicam induced exanthematous pustulosis her liver function tests were: Aspartate transaminase 38 U/ml, In this case, the clinical presentation and histology of a skin bilirubin 9 µmol/l and alkaline phosphatase 88 U/ml. A skin biopsy were consistent with AGEP. Resolution began without biopsy specimen revealed well‑developed subcorneal pustules further use of piroxicam, which advocates the diagnosis in associated with epidermal spongiosis. Scattered neutrophils retrospect. The other medications (nifedipine, captopril, as well as eosinophils were noted within the dermis (According indapamide, glibenclamide, glimepiride and simvastatin) were to the EuroSCAR score, the most of criteria have been met by continued. This association could have been strengthened by our patient who had a score of 9). Within a week of piroxicam performing patch test with piroxicam.[11] Due to the self‑limited withdrawal, the patient’s lesions gradually began clearing. and benign course of this disease, treatment is usually not The patient remained on the same therapies for her arterial necessary except for symptomatic therapy and withdrawal of the hypertension, diabetes mellitus and dyslipidemia. culprit drug.[8] Some cases have been treated with intravenous hydrocortisone, oral prednisolone or methylprednisolone or Discussion topical agents alone.[9,10] Drugs like infliximab were used in an AGEP is a rare pustular severe cutaneous adverse reaction over lop of AGEP‑toxic epidermal necrolysis.[10] In our case, the that generally presents with an acute edematous erythema and withdrawal of piroxicam was sufficient to resolve all clinical small non‑follicular sterile pustules mostly beginning in folds features in only 1 week. or face and within hours becomes diffuse. Skin symptoms are almost always accompanied by fever (≥38°C) and leukocytosis References with a high neurophil count (≥7000/µl). Other skin symptoms 1. Turk BG, Gunaydin A, Ertam I, Ozturk G. Adverse cutaneous drug reactions among such as marked edema of the face, purpura, blisters and vesicles hospitalized patients: Five year surveillance. Cutan Ocul Toxicol 2013;32:41‑5. have been described.[3] Additional systemic manifestations 2. Wedi B. Definitions and mechanisms of drug hypersensitivity. Expert Rev Clin Pharmacol 2010;3:539‑51. include mild eosinophilia, lymphadenopathy, acute renal failure 3. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized and a mild elevation of liver enzymes.[1,3,9] exanthematous pustulosis (AGEP) – A clinical reaction pattern. J Cutan Pathol The multinational epidemiological case‑control study on 2001;28:113‑9. severe cutaneous adverse reactions (EuroSCAR‑project) has 4. Haro‑Gabaldón V, Sánchez‑Sánchez‑Vizcaino J, Ruiz‑Avila P, developed and used the well‑defined EuroSCAR group criteria to Gutiérrez‑Fernández J, Linares J, Naranjo‑Sintes R. Acute generalized [3] exanthematous pustulosis with cytomegalovirus infection. Int J Dermatol establish the diagnosis of AGEP. The accuracy of the EuroSCAR 1996;35:735‑7. [3,9] group criteria has been validated. It allots 0, 1 or 2 points for 5. Calistru AM, Lisboa C, Cunha AP, Bettencourt H, Azevedo F. Acute generalized each of 4 variables of morphology, −10, 0, 1, 2 or 3 for each of 5 exanthematous pustulosis to amoxicillin associated with parvovirus B19 variables of histological findings. In addition, it assigns −4, −2, reactivation. Cutan Ocul Toxicol 2012;31:258‑61. 0 or 1 for each of 5 items of the disease’s course. Its involved 6. Lim CS, Lim SL. Acute generalized exanthematous pustulosis associated with asymptomatic Mycoplasma pneumoniae infection. Arch Dermatol 2009;145:848‑9. items yield causality levels of definite with a scale at 8‑12 7. Manzano S, Guggisberg D, Hammann C, Laubscher B. Acute generalized points, probable (5‑7 points), possible (1‑4 points) and excluded exanthematous pustulosis: First case associated with a Chlamydia pneumoniae AGEP (0 point).[3] The range of the score is between −18 and 12. infection. Arch Pediatr 2006;13:1230‑2. In our case, the EuroSCAR score was 9 and therefore, the case 8. Davidovici BB, Pavel D, Cagnano E, Rozenman D, Halevy S, EuroSCAR, et al. was specified as definite AGEP. Acute generalized exanthematous pustulosis following a spider bite: Report of Histological findings show subcorneal and/or intraepidermal 3 cases. J Am Acad Dermatol 2006;55:525‑9. 9. Chang SL, Huang YH, Yang CH, Hu S, Hong HS. Clinical manifestations and pustules, with pronounced edema in the papillary dermis and a characteristics of patients with acute generalized exanthematous pustulosis in perivascular infiltrate of neutrophils and eosinophils.[3] Asia. Acta Derm Venereol 2008;88:363‑5. A wide spectrum of cutaneous diseases or reactions is 10. Peermohamed S, Haber RM. Acute generalized exanthematous pustulosis associated with pustular eruptions.[10] However, the chief simulating toxic epidermal necrolysis: A case report and review of the literature. differential diagnosis would include pustular psoriasis.[3,11] Arch Dermatol 2011;147:697‑701. [3] 11. Speeckaert MM, Speeckaert R, Lambert J, Brochez L. Acute generalized Most cases of AGEP have been attributed to drug reactions. exanthematous pustulosis: An overview of the clinical, immunological and [12] Roujeau et al. found that 87% of cases resulted from drug diagnostic concepts. Eur J Dermatol 2010;20:425‑33. reactions. Studies show that antibiotics were the most common 12. Roujeau JC, Bioulac‑Sage P, Bourseau C, Guillaume JC, Bernard P, Lok C, et al. drugs implicated (75%), with no attributes to non‑steroidal Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol anti‑inflammatory drugs (NSAIDs). Furthermore, there is an 1991;127:1333‑8. [1,3,11] 13. Rastogi S, Modi M, Dhawan V. Acute localized exanthematous pustulosis (ALEP) increasing number of cases caused by anti‑fungals. A study caused by Ibuprofen. A case report. Br J Oral Maxillofac Surg 2009;47:132‑4. [9] done by Chang et al. analyzed 16 cases of AGEP with a 14. Ziemssen T, Bauer A, Bär M. Potential side effect of high‑dose corticosteroid relatively low association with systemic drugs (62.5%), there relapse treatment: Acute generalized exanthematous pustulosis (AGEP). Mult was no case of causative NSAIDs. There have been few cases Scler 2009;15:275‑7. implicating NSAIDs,[1] including ibuprofen,[13] diclofenac,[1,11] Cite this article as: Cherif Y, Jallouli M, Mseddi M, Turki H, Bahloul Z. Acute topical bufexamac, naproxen and phenylbutazone.[11] As generalized exanthematous pustulosis induced by piroxicam: A case report. corticosteroids are commonly used in the treatment of severe Indian J Pharmacol 2014;46:232-3. AGEP; they nevertheless, may trigger severe and rare AGEP.[14] Source of Support: Nil.
Recommended publications
  • Allergic and Photoallergic Contact Dermatitis to Topical Non-Steroidal Anti-Inflammatory Drugs: a Case Series from Turkey
    CONTACT DERMATITIS AND OCCUPATIONAL DERMATOSES ALLERGIC AND PHOTOALLERGIC CONTACT DERMATITIS TO TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS: A CASE SERIES FROM TURKEY E Ozkaya (1) - A Kutlay (1) Istanbul University Istanbul Medical Faculty, Dermatology, Istanbul, Turkey (1) Background: Topical non-steroidal anti-inflammatory drugs (NSAIDs) are widely used, mainly for soft tissue pain and injury. Allergic contact dermatitis (ACD) and photoallergic contact dermatitis (PACD) from topical NSAIDs have been reported with an increasing incidence. Ketoprofen seems to be the major culprit drug, followed by etofenamate and bufexamac in many European countries. There are only limited data on this subject in Turkey. Observation: Out of 2375 consecutively patch tested patients in our clinic between 1996 and 2017, 13 patients (7 male, 6 female, age range: 21-81, median: 56 years) (0.5%) were diagnosed with topical NSAID-induced ACD/PACD. Patients were patch tested (n=13) and photopatch tested (n=4) with the suspected topical preparations as is, and with the active (n=4) and inactive ingredients, when available, in addition to the European baseline series. Etofenamate (tested in a dilution series of 1%-5%-10% in petrolatum and aqua) was the leading culprit drug in 8 patients (62%), followed by ketoprofen (n=2), diclofenac (n=2), and diethylamine salicylate & naproxen (n=1). The main diagnosis was ACD whereas PACD was diagnosed in 2 patients from etofenamate and ketoprofen. Concomitant positive reaction were observed with inactive ingredients such as benzyl alcohol in etofenamate, and neroli oil in ketoprofen preparations, respectively. Cross-reaction to fragrances (fragrance mix I, balsam of Peru, cinnamic alcohol/aldehyde) was present in both patients with ketoprofen allergy.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group M01 (Antiinflammatory and antirheumatic products) Table of Contents Page INTRODUCTION 6 DISCLAIMER 8 GLOSSARY OF TERMS USED IN THIS DOCUMENT 9 ACTIVE SUBSTANCES Phenylbutazone (ATC: M01AA01) 11 Mofebutazone (ATC: M01AA02) 17 Oxyphenbutazone (ATC: M01AA03) 18 Clofezone (ATC: M01AA05) 19 Kebuzone (ATC: M01AA06) 20 Indometacin (ATC: M01AB01) 21 Sulindac (ATC: M01AB02) 25 Tolmetin (ATC: M01AB03) 30 Zomepirac (ATC: M01AB04) 33 Diclofenac (ATC: M01AB05) 34 Alclofenac (ATC: M01AB06) 39 Bumadizone (ATC: M01AB07) 40 Etodolac (ATC: M01AB08) 41 Lonazolac (ATC: M01AB09) 45 Fentiazac (ATC: M01AB10) 46 Acemetacin (ATC: M01AB11) 48 Difenpiramide (ATC: M01AB12) 53 Oxametacin (ATC: M01AB13) 54 Proglumetacin (ATC: M01AB14) 55 Ketorolac (ATC: M01AB15) 57 Aceclofenac (ATC: M01AB16) 63 Bufexamac (ATC: M01AB17) 67 2 Indometacin, Combinations (ATC: M01AB51) 68 Diclofenac, Combinations (ATC: M01AB55) 69 Piroxicam (ATC: M01AC01) 73 Tenoxicam (ATC: M01AC02) 77 Droxicam (ATC: M01AC04) 82 Lornoxicam (ATC: M01AC05) 83 Meloxicam (ATC: M01AC06) 87 Meloxicam, Combinations (ATC: M01AC56) 91 Ibuprofen (ATC: M01AE01) 92 Naproxen (ATC: M01AE02) 98 Ketoprofen (ATC: M01AE03) 104 Fenoprofen (ATC: M01AE04) 109 Fenbufen (ATC: M01AE05) 112 Benoxaprofen (ATC: M01AE06) 113 Suprofen (ATC: M01AE07) 114 Pirprofen (ATC: M01AE08) 115 Flurbiprofen (ATC: M01AE09) 116 Indoprofen (ATC: M01AE10) 120 Tiaprofenic Acid (ATC:
    [Show full text]
  • Consultation: Proposed Amendments to the Poisons Standard – ACMS, June 2021 27 April 2021
    Consultation: Proposed amendments to the Poisons Standard – ACMS, June 2021 27 April 2021 Therapeutic Goods Administration Copyright © Commonwealth of Australia 2021 This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <[email protected]> Confidentiality All submissions received will be placed on the TGA’s Internet site, unless marked confidential. Any confidential material contained within your submission should be provided under a separate cover and clearly marked “IN CONFIDENCE”. Reasons for a claim to confidentiality must be included in the space provided on the TGA submission form. For submission made by individuals, all personal details, other than your name, will be removed from your submission before it is published on the TGA’s Internet site. In addition, a list of parties making submissions will be published.
    [Show full text]
  • Topical Nsaids for Chronic Musculoskeletal Pain in Adults (Review)
    Cochrane Database of Systematic Reviews Topical NSAIDs for chronic musculoskeletal pain in adults (Review) Derry S, Conaghan P, Da Silva JAP, Wiffen PJ, Moore RA Derry S, Conaghan P, Da Silva JAP, Wiffen PJ, Moore RA. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD007400. DOI: 10.1002/14651858.CD007400.pub3. www.cochranelibrary.com Topical NSAIDs for chronic musculoskeletal pain in adults (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 6 OBJECTIVES ..................................... 7 METHODS ...................................... 7 RESULTS....................................... 10 Figure1. ..................................... 11 Figure2. ..................................... 14 Figure3. ..................................... 16 Figure4. ..................................... 17 Figure5. ..................................... 20 DISCUSSION ..................................... 22 Figure6. ..................................... 23 AUTHORS’CONCLUSIONS . 24 ACKNOWLEDGEMENTS . 25 REFERENCES ..................................... 26 CHARACTERISTICSOFSTUDIES . 31 DATAANDANALYSES. 73 Analysis 1.1. Comparison 1 Topical diclofenac versus carrier, Outcome 1 Clinical success. 74 Analysis
    [Show full text]
  • Plants As Sources of Anti-Inflammatory Agents
    molecules Review Plants as Sources of Anti-Inflammatory Agents Clara dos Reis Nunes 1 , Mariana Barreto Arantes 1, Silvia Menezes de Faria Pereira 1, Larissa Leandro da Cruz 1, Michel de Souza Passos 2, Luana Pereira de Moraes 1, Ivo José Curcino Vieira 2 and Daniela Barros de Oliveira 1,* 1 Laboratório de Tecnologia de Alimentos, Centro de Ciências e Tecnologias Agropecuárias, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ 28013-602, Brazil; [email protected] (C.d.R.N.); [email protected] (M.B.A.); [email protected] (S.M.d.F.P.); [email protected] (L.L.d.C.); [email protected] (L.P.d.M.) 2 Laboratório de Ciências Químicas, Centro de Ciências e Tecnologia, UniversidadeEstadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ 28013-602, Brazil; [email protected] (M.d.S.P.); [email protected] (I.J.C.V.) * Correspondence: [email protected]; Tel.: +55-22-988395160 Academic Editors: Thea Magrone, Rodrigo Valenzuela and Karel Šmejkal Received: 29 June 2020; Accepted: 5 August 2020; Published: 15 August 2020 Abstract: Plants represent the main source of molecules for the development of new drugs, which intensifies the interest of transnational industries in searching for substances obtained from plant sources, especially since the vast majority of species have not yet been studied chemically or biologically, particularly concerning anti-inflammatory action. Anti-inflammatory drugs can interfere in the pathophysiological process of inflammation, to minimize tissue damage and provide greater comfort to the patient. Therefore, it is important to note that due to the existence of a large number of species available for research, the successful development of new naturally occurring anti-inflammatory drugs depends mainly on a multidisciplinary effort to find new molecules.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,674,488 B2 Masuda Et Al
    USOO7674488B2 (12) United States Patent (10) Patent No.: US 7,674,488 B2 Masuda et al. (45) Date of Patent: Mar. 9, 2010 (54) EXTERNAL COMPOSITION COMPRISING 2005. O142236 A1 6/2005 Horie et al. AN AQUEOUS EXTRACT OF RED VINE 2005/0202110 A1 9, 2005 Horie et al. LEAVES AND AN ANTI-NFLAMMATORY 2005/0271 757 A1 12/2005 Masuda et al. AGENT 2006, OO68043 A1 3/2006 Esperester (75) Inventors: Kenji Masuda, Soka (JP); Kazuki 2006, O198913 A1 9, 2006 Sacher Matsumoto, Sakura (JP); Minoru Okada, Inzai (JP); Koichi Takahashi, Tomisato (JP) FOREIGN PATENT DOCUMENTS (73) Assignee: Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE) CA 2512149 A1 T 2004 EP O694305 A1 1, 1996 (*) Notice: Subject to any disclaimer, the term of this FR 2276959 A1 6, 1974 patent is extended or adjusted under 35 GB 934554 8, 1963 U.S.C. 154(b) by 228 days. JP 59040853 * 3, 1984 RU 2195262 * 12/2002 (21) Appl. No.: 11/061.556 WO 99.29331 A1 6, 1999 (22) Filed: Feb. 18, 2005 WO O128363 A1 4/2001 WO 020721 18 A1 9, 2002 (65) Prior Publication Data WO 2004-0582.27 A1 T 2004 US 2005/0271 757 A1 Dec. 8, 2005 (30) Foreign Application Priority Data OTHER PUBLICATIONS Feb. 19, 2004 (EP) .................................. O4OO3705 Kiesewetter et al. Arzneimittel-Forschung. 2000. vol. 50, No. 2, pp. (51) Int. Cl. 109-117.* A6 IK 36/00 (2006.01) Bastin et al. Organic Process Res. Devel. 2000. vol. 4, pp. 427-435.* (52) U.S. Cl. ....................................... 424/774; 424/725 Endotelon, SanofiPharma AG.
    [Show full text]
  • Repurposing Drugs for COVID-19 Based on Transcriptional Response of Host Cells to SARS-Cov-2
    Repurposing drugs for COVID-19 based on transcriptional response of host cells to SARS-CoV-2 Fuhai Li1,2#, Andrew P. Michelson1,3, Randi Foraker1, Ming Zhan4, Philip R.O. Payne1 1Institute for Informatics (I2), 2Department of Pediatrics, 3Pulmonary and Critical Care Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; 4National Institute of Mental Health (NIMH), NIH, Bethesda, MD, USA. #Correspondence Email: [email protected] Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has infected over 10 million people globally with a relatively high mortality rate. There are many therapeutics undergoing clinical trials, but there is no effective vaccine or therapy for treatment thus far. After affected by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), molecular signaling of host cells play critical roles during the life cycle of SARS-CoV-2, like RNA replication, assembly. Thus, it is significant to identify the involved molecular signaling pathways within the host cells, and drugs targeting on these molecular signaling pathways could be potentially effective for COVID-19 treatment. In this study, we aimed to identify these potential molecular signaling pathways, and repurpose existing drugs as potential effective treatment of COVID-19 to facilitate the therapeutic discovery, based on the transcriptional response of host cells. We first identified dysfunctional signaling pathways associated with the infection caused SARS-CoV-2 in human lung epithelial cells through analysis of the altered gene expression profiles. In addition to the signaling pathway analysis, the activated gene ontologies (GOs) and super gene ontologies were identified. Signaling pathways and GOs such as MAPK, JNK, STAT, ERK, JAK-STAT, IRF7-NFkB signaling, and MYD88/CXCR6 immune signaling were particularly identified.
    [Show full text]
  • Use of Nonsteroidal Anti-Inflammatory Agents and Risk of Melanoma and Non-Melanoma
    Use of Nonsteroidal Anti-Inflammatory Agents and Risk of Melanoma and Non-Melanoma Skin Cancer by Santhosh Reddy Mukkisa Special Project Submitted to the School of Health Sciences Eastern Michigan University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in Clinical Research Administration Project Advisor: Irwin Martin, Ph.D., Jean Rowan, MD, MS. April 25, 2018 Ypsilanti, Michigan Acknowledgments I would like to express my gratitude to my Professor, Dr. Irwin G. Martin, for his continuous support and constructive suggestions throughout the project. I would like to thank Dr. Jean Rowan for some important insight on this topic and providing useful input. I would also like to thank my family and my friends for their continued support and encouragement throughout this course. NSAIDs Use and Risk of Skin Cancer Abstract Skin cancer (melanoma and non-melanoma skin cancer) is one of the common types of cancer in most of the countries. Several studies have assessed the chemoprevention effect of NSAIDs in melanoma and non-melanoma skin cancer. A few studies support the chemopreventive effect of NSAIDs on skin cancer and some do not. There is conflicting evidence regarding NSAID use and risk of skin cancer risk. In view of these inconsistent results, a detailed meta-analysis to explore the role of NSAIDs in melanoma and non- melanoma skin cancer prevention was undertaken. The present study assessed the role of NSAIDs (both aspirin and non-aspirin NSAIDs) as chemopreventive agents for melanoma and non-melanoma skin cancer. Meta- analysis of 15 studies showed that NSAIDs might have a chemopreventive effect in prevention of melanoma skin cancer.
    [Show full text]
  • Uniform Classification Guidelines for Foreign Substances and Recommended Penalties Model Rule
    DRUG TESTING STANDARDS AND PRACTICES PROGRAM. Uniform Classification Guidelines for Foreign Substances And Recommended Penalties Model Rule. January, 2018 (V.13.4) ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2018. Association of Racing Commissioners International 1510 Newtown Pike, Lexington, Kentucky, United States www.arci.com Page 1 of 61 Preamble to the Uniform Classification Guidelines of Foreign Substances The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991. "The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalities to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered.
    [Show full text]
  • Anti-Inflammatory Effect of Diclofenac-Sodium Ointment (Cream) in Topical Application
    ANTI-INFLAMMATORY EFFECT OF DICLOFENAC-SODIUM OINTMENT (CREAM) IN TOPICAL APPLICATION Kohei KYUKI, Tomohisa SHIBUYA, Kaito TSURUMI and Hajime FUJIMURA Department of Pharmacology, Gifu University School of Medicine, 40 Tsukasamachi, Gifu 500, Japan Accepted September 16, 1982 Abstract-This study was performed to develop a topical ointment of diclofenac-Na which has a potent anti-inflammatory activity by oral administration. At first, research was carried out on the ointment base which influences the external anti-inflammatory effect of the drug. Ointments of diclofenac-Na were prepared with three kinds of bases: lipophilic, emulsion (cream) and gel bases; and their anti-inflammatory effects were compared. The cream was found to have the most potent effect. Therefore, in the next experiment, an optimum concentration of diclofenac-Na in cream was determined comparing the anti-inflammatory effect among the cream preparations containing 0.5, 0.75, 1.0 and 1.5% of the drug. Obvious effects were observed with the cream containing 1.0% and 1.5% of the drug concentration, and there was no significant difference in the anti-inflammatory activities of these two concentrations. Based on these results, the cream preparation containing 1.0% of diclofenac-Na (DF cream) was adopted as the external ointment of the drug. The anti-inflammatory effect of this cream was compared with that of existing anti-inflammatory ointments, i.e., indomethacin gel (IM gel), bufexamac cream (BM cream) and mobilat ointment (ML ointment). DF cream produced obvious inhibition on increased vascular permeability and on acute edema and remarkable suppression of ultraviolet erythema. These activities of DF cream were similar to those of I M gel and more potent than those of BM cream and M L ointment.
    [Show full text]
  • Contents Appendix 1A: List of Exposure Drugs in Nsaids and Pneumonia Analysis
    Contents Appendix 1a: List of exposure drugs in NSAIDs and Pneumonia analysis ................................................ 2 Appendix 1b: List of comparator drugs in NSAIDs and Pneumonia analysis ............................................ 3 Appendix 2: List of ICD-9 codes used to define upper respiratory disease for subgroup analysis in NSAIDs and pneumonia example .............................................................................................................. 4 Appendix 3: Association between non-selective NSAIDs and GI bleed .................................................... 5 Appendix 1a: List of exposure drugs in NSAIDs and Pneumonia analysis Butylpyrazolidines Acetic acid Oxicams Propionic acid Fenamates Coxibs Other derivatives and derivatives** related Phenylbutazone indometacin piroxicam ibuprofen mefenamic acid celecoxib nabumetone Mofebutazone sulindac tenoxicam naproxen tolfenamic acid rofecoxib niflumic acid Oxyphenbutazone tolmetin droxicam ketoprofen flufenamic acid valdecoxib azapropazone Clofezone meclofenamic zomepirac lornoxicam fenoprofen acid parecoxib glucosamine Kebuzone diclofenac meloxicam fenbufen etoricoxib benzydamine meloxicam, glucosaminoglycan alclofenac combinations benoxaprofen lumiracoxib polysulfate bumadizone suprofen polmacoxib proquazone etodolac pirprofen orgotein lonazolac flurbiprofen nimesulide fentiazac indoprofen feprazone acemetacin tiaprofenic acid diacerein difenpiramide oxaprozin morniflumate oxametacin ibuproxam tenidap proglumetacin dexibuprofen oxaceprol ketorolac
    [Show full text]
  • Pharmaceuticals: Restrictions in Use and Availability
    WHO/EMP/QSM/2010.3 PHARMACEUTICALS: RESTRICTIONS IN USE AND AVAILABILITY PHARMACEUTICALS: RESTRICTIONS IN USE AND AVAILABILITY Prepared within the context of the United Nations publication "Consolidated List of Products whose Consumption and/or Sale have been Banned, Withdrawn, Severely Restricted or Not Approved by Governments" Update of the Fourteenth Issue 2010 Essential Medicines and Pharmaceutical Policies Quality Assurance and Safety: Medicines Health Systems and Services © World Health Organization 2010 All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: 1). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Marketing and Dissemination, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]